Economic evaluations of implemented vaccination programmes: Key methodological challenges in retrospective analyses

Vaccine

Volumn 32, Issue 7, 2014, Pages 759-765

  Newall, A T ^a   Reyes, J F ^a   Wood, J G ^a   McIntyre, P ^b   Menzies, R ^b   Beutels, P ^a,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Cost effectiveness; Economic evaluation; Post implementation; Programme evaluation; Retrospective; Vaccination

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; ECONOMIC EVALUATION; EVALUATION STUDY; HEALTH PROGRAM; HUMAN; METHODOLOGY; PRIORITY JOURNAL; PROGRAM IMPACT; RETROSPECTIVE STUDY; REVIEW; STANDARD; VACCINATION;

COST-EFFECTIVENESS; ECONOMIC EVALUATION; POST-IMPLEMENTATION; PROGRAMME EVALUATION; RETROSPECTIVE; VACCINATION;

COST-BENEFIT ANALYSIS; EVALUATION STUDIES AS TOPIC; FORECASTING; HUMANS; IMMUNIZATION PROGRAMS; RESEARCH DESIGN; RETROSPECTIVE STUDIES;

EID: 84892856887     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.11.067     Document Type: Review

References (37)

1. Beutels P., Scuffham P.A., MacIntyre C.R. Funding of drugs: do vaccines warrant a different approachα. Lancet Infect Dis 2008, 8(11):727-733.
2. Framework for program evaluation in public health MMWR Recommendations and reports: Morbidity and mortality weekly report recommendations and reports/centers for disease control 1999, 48 (RR-11). pp. 1-40.
3. Bilcke J., Beutels P., Brisson M., Jit M. Accounting for methodological, structural, and parameter uncertainty in decision-analytic models: a practical guide. Med Decis Making 2011, 31(4):675-692.
4. Walker D.G., Hutubessy R., Beutels P. WHO guide for standardisation of economic evaluations of immunization programmes. Vaccine 2010, 28(11):2356-2359.
5. Brisson M., Edmunds W.J. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making 2003, 23(1):76-82.
6. Fine P.E.M. Herd immunity: history, theory, practice. Epidemiol Rev 1993, 15(2):265-302.
7. Isaacman D.J., McIntosh E.D., Reinert R.R. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Inter J Infect Dis 2010, 14(3):e197-e199.
8. Ehreth J. The value of vaccination: a global perspective. Vaccine 2003, 21(27-30):4105-4117.
9. Burgess M.A., McIntyre P.B. Vaccines: the new Australian best-practice schedule. Med J Aust 2004, 180(10):494-496.
10. Walker S., Sculpher M., Claxton K., Palmer S. Coverage with evidence development, only in research, risk sharing, or patient access schemeα A framework for coverage decisions. Value Health 2012, 15(3):570-579.
11. Plotkin S., Orenstein W., Offit P. Vaccines 2008, Saunders Elsevier.
12. Kieninger D.M., Kueper K., Steul K., Juergens C., Ahlers N., Baker S., et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine 2010, 28(25):4192-4203.
13. Vesikari T.M.D., Wysocki J.M.D., Chevallier B.M.D., Karvonen A.M.D., Czajka H.M.D., Arsene J-P.M.D., et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009, 28(4):S66-S76.
14. Skinner J.M., Indrawati L., Cannon J., Blue J., Winters M., MacNair J., et al. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model. Vaccine 2011, 29(48):8870-8876.
15. Lehtinen M., Dillner J. Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol 2013, 10(7):400-410.
16. Newall A.T., Creighton P., Philp D.J., Wood J.G., MacIntyre C.R. The potential cost-effectiveness of infant pneumococcal vaccines in Australia. Vaccine 2011, 29(45):8077-8085.
17. Murray C.J., Frenk J. Health metrics and evaluation: strengthening the science. Lancet 2008, 371(9619):1191-1199.
18. McCabe C., Dixon S. Testing the validity of cost-effectiveness models. Pharmacoeconomics 2000, 17(5):501-513.
19. Lieu T.A., Ray G.T., Black S.B., Butler J.C., Klein J.O., Brelman R.F., et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. J Am Med Assoc 2000, 283(11):1460-1468.
20. Ray G.T., Pelton S.I., Klugman K.P., Strutton D.R., Moore M.R. Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States. Vaccine 2009, 27(47):6483-6494.
21. Grijalva C.G., Nuorti J.P., Arbogast P.G., Martin S.W., Edwards K.M., Griffin M.R. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007, 369(9568):1179-1186.
22. Poehling K.A., Szilagyi P.G., Grijalva C.G., Martin S.W., LaFleur B., Mitchel E., et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics 2007, 119(4):707-715.
23. Quinn H.E., McIntyre P.B. The impact of adolescent pertussis immunization, 2004-2009: lessons from Australia. Bull World Health Organ 2011, 89(9):666-674.
24. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348(18):1737-1746.
25. Brotherton J.M., Fridman M., May C.L., Chappell G., Saville A.M., Gertig D.M. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011, 377(9783):2085-2092.
26. Jardine A., Menzies R.I., McIntyre P.B. Reduction in hospitalizations for pneumonia associated with the introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia. Pediatr Infect Dis J 2010, 29(7):607-612.
27. Minalu G., Aerts M., Coenen S., Versporten A., Muller A., Adriaenssens N., et al. Application of mixed-effects models to study the country-specific outpatient antibiotic use in Europe: a tutorial on longitudinal data analysis. J Antimicrob Chemother 2011, 66:79-87.
28. Hens N., Kvitkovicova A., Aerts M., Hlubinka D., Beutels P. Modelling distortions in seroprevalence data using change-point fractional polynomials. Statistical Model 2010, 10(2):159-175.
29. Black S.B., Shinefield H.R., Ling S., Hansen J.R., Fireman B., Spring D., et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002, 21(9):810-815.
30. Simonsen L., Taylor R.J., Viboud C., Miller M.A., Jackson L.A. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007, 7(10):658-666.
31. Trotter C.L., Edmunds W.J. Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model. Med Decis Making 2006, 26(1):38-47.
32. Sander B., Kwong J.C., Bauch C.T., Maetzel A., McGeer A., Raboud J.M., et al. Economic appraisal of Ontario's universal influenza immunization program: a cost-utility analysis. PLoS Med 2010, 7(4):e1000256.
33. de Greeff S.C., Lugner A.K., van den Heuvel D.M., Mooi F.R., de Melker H.E. Economic analysis of pertussis illness in the Dutch population: implications for current and future vaccination strategies. Vaccine 2009, 27(13):1932-1937.
34. Grimes D.A., Schulz K.F. An overview of clinical research: the lay of the land. Lancet 2002, 359(9300):57-61.
35. Rozenbaum M.H., Sanders E.A., van Hoek A.J., Jansen A.G., van der Ende A., van den Dobbelsteen G., et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ 2010, 340:c2509.
36. Drummond M., Sculpher M.J., Torrance G.W., O'Brien B.J., Stoddart G.L. Methods for the economic evaluation of health care programmes 2005, Oxford University Press, Oxford. 3rd ed.
37. Hoyle M. Future drug prices and cost-effectiveness analyses. Pharmacoeconomics 2008, 26(7):589-602.